Sequence‐Selective DNA Recognition with Peptide–Bisbenzamidine Conjugates by Sánchez López, Mateo Isidro et al.
 






Sequence-Selective DNA Recognition with Peptide–
Bisbenzamidine Conjugates 
Mateo I. Sánchez, Olalla Vázquez. M. Eugenio Vázquez, José L. Mascareñas 
 
Peer reviewed version 
 
This is the peer reviewed version of the following article: Sánchez, M. I., Vázquez, O., Vázquez, M. 
E. and Mascareñas, J. L. (2013), Sequence-Selective DNA Recognition with Peptide–Bisbenzamidine 
Conjugates. Chem. Eur. J., 19: 9923-9929, which has been published in final form at 
https://doi.org/10.1002/chem.201300519. This article may be used for non-commercial purposes 
in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions 
 
How to cite: 
Sánchez, M. I., Vázquez, O., Vázquez, M. E. and Mascareñas, J. L. (2013), Sequence-Selective DNA 




© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. This article may be used for non-





DOI: 10.1002/chem.200((will be filled in by the editorial staff))
Sequence-Selective DNA Recognition with peptide-bisbenzamidine conjugates  
Mateo I. Sánchez, Olalla Vázquez, M. Eugenio Vázquez,* and José L. Mascareñas*[a] 
 
Abstract: Transcription factors (TFs) 
are specialized proteins that play a key 
role in the regulation of genetic 
expression. Their mechanism of action 
involves the interaction with specific 
DNA sequences, which usually takes 
place through specialized domains of 
the protein. However, achieving an 
efficient binding usually requires the 
presence of the full protein. This is the 
case for bZIP and zinc finger TF 
families, which cannot interact with 
their target sites when the DNA binding 
fragments are presented as isolated 
monomers. Herein we demonstrate that 
the DNA binding of these monomeric 
peptides can be restored when 
conjugated to aza-bisbenzamidines, 
readily accessible molecules that 
interact with AT rich sites by insertion 
into their minor groove. Importantly, 
the fluorogenic properties of the aza-
benzamidine unit allow to obtain details 
of the DNA interaction that are eluded 
in electrophoresis mobility shift assays 
(EMSA). The hybrids based on the 
GCN4 bZIP protein preferentially bind 
to composite sequences containing 
tandem bisbenzamidine-GCN4 binding 
sites (TCAT·AAATT). Fluorescence 
reverse titrations show an interesting 
multiphasic profile consistent with the 
formation of competitive nonspecific 
complexes at low DNA/peptide ratios. 
On the other hand, the conjugate with 
the DNA binding domain of the zinc 
finger protein GAGA binds with high 
affinity (KD ≈ 12 nM) and specificity to 
a composite AATTT·GAGA sequence 
containing both the bisbenzamidine and 
the TF consensus binding sites.  
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DNA binding • fluorescence • 
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Introduction 
Gene expression is regulated by the action of specialized proteins 
called Transcription Factors (TFs) that bind to specific DNA 
regulatory sequences,1 and hereafter promote the assembly of the 
multiprotein complex directly responsible for the initiation of 
transcription.2 As a consequence of their fundamental role in the 
regulation of gene expression, it is not surprising that alterations in 
the activity of TFs are at the origin of many diseases, including 
cancer.3 Therefore, the development of non-natural agents that can 
emulate or interfere with the dsDNA recognition of TFs remains a 
major goal in biological chemistry. These agents might have a great 
impact in fundamental and applied biological research, and even 
lead to the development of gene-targeted therapies.4  It is well 
established that although the DNA-binding of TF is mediated by 
relatively small peptide motifs, high-affinity DNA binding requires 
the full protein domain and, in many cases, the concerted action of 
multiple binding components.5 Therefore, the preparation of small 
synthetic mimics of DNA-binding proteins is extremely challenging. 
Chemists have been able to engineer relatively small peptides 
capable of interacting with good affinity to specific dsDNA 
sequences.6 Our own approach for the design of such minimized 
systems has relied on the conjugation of small peptide fragments 
derived from the DNA binding domains of transcription factors to 
tripyrrolic distamycin derivatives that bind to the minor groove of 
A/T-rich DNA sequences.7 Although the strategy is effective, the 
synthesis of the tripyrrole moiety requires more than seven steps, 
and the handling of relatively unstable aminopyrrole synthetic 
intermediates. Therefore the use of other minor groove binding 
moieties that could be synthetically more accessible represents an 
important goal. In this context, we were attracted by propamidine 
and its derivatives, well-known A/T-rich DNA binders that display a 
much simpler structure than that of distamycin-related polyamides. 8 
Herein we describe the synthesis of a hybrid between the basic 
region of GCN4 and propamidine, and demonstrate by 
electrophoresis mobility shift assays (EMSA) that this conjugate is 
capable of binding to designed DNA sites with good selectivity. 
More importantly, following our recent discovery of aza-
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bisbenzamidines as highly sensitive fluorogenic minor groove DNA 
binding agents,8a,9  we also describe the synthesis of conjugates 
between one of these minor groove binders and fragments of the 
GCN4 and GAGA proteins, two representative members of the bZIP 
and zinc-finger families of transcription factors. In these conjugates, 
the aza-bisbenzamidine derivative not only promotes the interaction 
of the peptide with the DNA, but also acts as a sensing device that 
allows spectroscopic monitoring of the DNA binding process in 
solution. 
Results and Discussion 
Synthesis of the GCN4-propamidine hybrid (GCN4-pr). The 
design of the GCN4-propamidine conjugate was based on the GCN4 
peptide fragment comprising residues Asp226 to Gln248, which has 
been identified as the smallest peptide that retains specific DNA 
recognition properties as a dimer,10 and was used in our previous 
studies with the tripyrrole conjugates.7e On the other hand, the 
propamidine derivative containing an appropriate linker for 
conjugation (3) was readily synthesized in three steps from 
commercially available p-fluorobenzonitrile (Scheme 1). The 
resulting propamidine-amino derivative was conjugated to the 
peptide fragment while it is still attached to the resin and selectively 
deprotected at glutamic acid 245, which replaces a native Arg 
residue in that position. After standard deprotection/cleavage and 
reverse-phase HPLC purification, the expected conjugate GCN4-pr 
was obtained in a good overall yield. 
 
Scheme 1. Top: Synthesis of the propamidine derivative (3) for conjugation with the 
peptide. Bottom: Key steps in the synthesis of the conjugate between 3 and a minimal 
basic region of the GCN4 transcription factor (Asp226 to Gln252, see the supporting 
information; we only indicate the key Glu required for the coupling). The allyl removal 
and the coupling steps are done while the peptide is still attached to the solid support. 
DNA binding studies of GCN4-pr. DNA binding experiments 
were carried out using standard non-denaturing EMSA protocols in 
polyacrylamide gels,11 and using ds-oligonucleotides containing a 
composite binding site including the consensus recognition 
sequences of the GCN4 basic region and the propamidine binder, in 
tandem (TCAT·AAATTT). As shown in Figure 1 (lanes 1-4), 
incubation of the target dsDNA oligo with the GCN4-pr hybrid 
leads to the formation of a relatively clean retention band, consistent 
with the formation of the desired complex in which the peptide 
derivative binds in major groove of its target sequence (TCAT), and 
the propamidine is inserted in the adjacent A/T-rich minor groove 
(AAATTT).  
 
Figure 1. EMSA GCN4-pr DNA binding assays in Tris-HCl buffer. Lanes 1-4; target 
AP1hs•AT dsDNA (50 nM), lanes 2-4: 100, 300, 500 nM GCN4-pr; lanes 5-8: control 
AP1hs•GC dsDNA (50 nM), lanes 6-8: 100, 300, 500 nM GCN4-pr; lanes 9-12: control 
GC•AT DNA (50 nM), lanes 10-12: 100, 300, 500 nM GCN4-pr. dsDNA sequences 
(binding site in italics, only one strand is shown): AP1hs•AT: 5’–CGAACG TCAT 
AAATTT CCTC–3’; AP1hs•GC: 5’–ACGAACG TCAT GGCC GCCTC–3’; GC•AT: 
5’–ACGAAG GCGGC AAATT CCTC–3’. Products were resolved by PAGE using a 
10% non-denaturing poliacrylamide gel and 0.5X TBE buffer for 40 min at rt., and 
analyzed by staining with SyBrGold (Molecular Probes: 5 µL in 50 mL of 1X TBE) for 
10 min, and fluorescence visualization. 
Consistent with that interaction model, circular dichroism 
experiments confirmed that the peptide chain folds into an α-helix 
upon interaction with this DNA, as expected for a specific 
recognition (see the supporting information). A control 
oligonucleotide lacking the A/T-rich site fails to provide DNA-
peptide complexes (Figure 1, lanes 5-8). On the other hand, 
incubation with oligonucleotides that do not exhibit a consensus 
peptide binding site (Figure 1, lanes 9-12), results in the formation 
of complexes of lower affinity that are more retained in the gel. 
These complexes most probably arise from non-specific DNA 
interactions involving the highly charged basic region, while the 
propamidine unit is inserted in the minor groove.7d,e Taken together, 
these results suggest that the propamidine is a viable alternative to 
the distamycin derivatives previously used as minor groove binders, 
although the performance in terms of affinity and selectivity seems 
poorer. 
 
Design and synthesis of bisbenzamidine conjugates of GCN4 
and GAGA transcription factors. At this stage of our research, we 
discovered that aza-bisbenzamidines, which feature a nitrogen 
instead of an oxygen atom at the para-position of the 
benzamidinium moiety, are weakly fluorescent in aqueous solvents 
but exhibit a great increase in the quantum yield of their 
fluorescence emission when bound to A/T-rich sites in the DNA.9 
We therefore envisioned the construction of a new type of hybrids 
featuring these chromophores as minor groove binding moieties, 
which might allow to gather information on the DNA interaction of 
the hybrids in solution by using spectroscopic methods. In particular, 
we decided to use as minor groove binding unit the phenol 
derivative 5, which can be synthesized in a single step from 
commercial products, and contains a hydroxyl handle to engineer 
the connection to the peptide chains. With this compound at hand, 
we did not only approach the construction of the hybrid with the 
basic region of GCN4, but also a conjugate with a truncated module 
of the zinc finger protein GAGA (Ser28 to Phe58), a 30 residue 
peptide that by itself is incapable of showing significant DNA 
affinity.7a,12 
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Figure 2. Left: schematic representation of the simultaneous interaction of the GCN4 
basic region peptide (gray cylinder) and the bisbenzamidine (orange block), indicating 
the Glu245 residue selected for conjugation. Right: representation of a simultaneous 
interaction of the DNA binding domain of the GAGA transcription factor fragment in 
the major groove, and the bisbenzamidine in the minor groove. In this case Lys44 is 
selected as an appropriate conjugation position. The models used to design the synthetic 
targets were based on the reported structures of the DNA binding complexes of the 
GCN4 and GAGA transcription factors,13 and that of pentamidine,14 as described in 
earlier reports of distamycin hybrids.7 
The design of the GCN4-bisbenzamidine hybrid (GCN4-bb) relies 
on the same Arg245 → Glu245 mutation of the GCN4 DNA binding 
domain fragment previously used for GCN4-pr. In this case, the 
conjugate was obtaining by coupling the aza-bisbenzamidine amine 
6, instead of the previously used propamidine-amine 3 (see the 
supporting information). Compound 6 was readily constructed by a 
reductive amination reaction between 4 and 5-hydroxyisophthalate, 
followed by alkylation of the phenolic oxygen in 5 with a Boc-
protected derivative of N-(5-iodopentyl)propane-1,3-diamine, and a 
final TFA deprotection. Therefore the synthesis of bisbenzamidine 6 
is straightforward, and involves only two separate steps from 
commercial and inexpensive starting materials.  
 
Scheme 2. Top: Synthesis of the bisbenzamidine aromatic derivative 6 by reductive 
amination of 5-hydroxyisophthalaldehyde, introduction of the aminoalkylic side chain 
in the phenolylc oxygen, and acidic deprotection. Bottom:  Key steps in the synthesis of 
GAGA-bb. The black circle represents the solid resin used in the peptide synthesis. 
The zinc finger conjugate was prepared from a peptide containing 
the truncated zinc finger unit of the GAGA transcription factor in 
which the Arg44 was replaced by Lys. This Lys44 was introduced 
with its side chain protected with an orthogonal alloc group that 
could be selectively removed in the solid phase (Scheme 2). The 
deprotected Lys side chain was then derivatized with glutaric 
anhydride, to increase the linker length and simultaneously install a 
carboxylic acid for attachment of the bisbenzamidine. Once the 
carboxylic acid functionality was set in the peptide scaffold, the 
bisbenzamidine 6 was coupled to the solid-phase linked peptide, 
using HATU as activating reagent. A standard cleavage and 
deprotection step involving treatment with a TFA cocktail, followed 
by reverse-phase HPLC purification gave the desired conjugate 
GAGA-bb in reasonable overall yield of ≈ 19 %. 
DNA binding studies of GCN4-bb and GAGA-bb conjugates. 
Having synthesized the desired peptide conjugates, we first assessed 
their DNA binding ability using standard EMSA experiments under 
non-denaturing conditions. Thus, incubation of the ds-
oligonucleotide AP1hs•AT, containing the target composite binding 
site (TCAT·AAATT) at room temperature with increasing amounts 
of GCN4-bb led to the appearance of two new bands in addition to 
that corresponding to the free DNA (Figure 3 top, lanes 1-5). The 
faster, more intense band, is consistent with the expected compact 
hybrid-DNA complex (band a), while the slower migrating band 
could result from a complex in which the bisbenzamidine unit is 
inserted into the minor groove of the A/T-rich region, while the 
extended peptide is making non-specific contacts with the DNA 
(Figure 3 top, band b). This assignment is supported by the 
observation of a similarly retarded band when GCN4-bb is 
incubated with an oligonucleotide featuring a mutated peptide-
binding site (AP1m•AT) (Figure 3 top, lanes 6-10).7e As expected, 
incubation of GCN4-bb with a G/C-rich or the AP1hs•GC control 
oligonucleotide did not show any new bands (see the supporting 
information). 
 
Figure 3. Top: EMSA assays of DNA recognition by GCN4-bb. Lanes 1-5: target 
AP1hs•AT dsDNA (50 nM). Lanes 2-5: 100, 300, 500, 800 nM GCN4-bb; lanes 6-10: 
control AP1m•AT dsDNA (50 nM). Lanes 7-10: 100, 300, 500, 800 nM GCN4-bb. 
Bottom: EMSA assays of DNA recognition by GAGA-bb. Lanes 1-7: target dsDNA 
AT•GAG (50 nM). Lanes 2-7: 100, 200, 300, 400, 500, 600 nM GAGA-bb. Lanes 8-
10: control ATm•GAG dsDNA (50 nM); lanes 9-10: 300, 500 nM GAGA-bb. dsDNA 
sequences (binding site in italics): AP1hs•AT: 5’–CGAACG TCAT AAATTT CCTC–3’; 
AP1m•AT: 5’–CGAACG TGCT AAATTT CCTC–3’; AT•GAG: 5’–GACGG AATTT 
GAGAG CGTCG–3’; ATm•GAG: 5’–GACC GGGCC GAGAG TACGT–3’.EMSA 
assays of DNA recognition by GCN4-bb were done in the same conditions as for 
GCN4-pr; in the case of GAGA-bb the buffer used was slightly different (see the 
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In the case of the conjugate GAGA-bb, we observed a single 
retarded band when treated with the AT•GAG oligonucleotide 
containing the composite binding site. This is consistent with the 
formation of the expected specific complex between the hybrid and 
the DNA (Figure 3 bottom, lanes 1-7). No retarded bands were 
observed when this same hybrid was incubated with a control 
dsDNA (ATm•GAG), lacking the minor groove recognition 
sequence (Figure 2 bottom, Lanes 8-10); likewise, incubation with a 
DNA containing the consensus minor groove binding sequence but a 
mutated peptide binding site failed to show any clear binding by 
EMSA (see the supporting information). The different behavior of 
the two conjugates (GCN4-bb and GAGA-bb) could be explained 
by the presence of a much higher number of basic residues in the 
case of the GCN4 hybrid, which promote electrostatic interactions 
with the negatively charged dsDNA, and hence the production of 
competitive less-specific DNA complexes. 
Steady-state fluorescence studies. The presence of the fluorogenic 
minor groove aza-bisbenzamidine in the new conjugates allows 
monitoring of the DNA binding process by fluorescent spectroscopy, 
and hence obtaining complementary information that could not be 
derived from the EMSA studies. Thus, incubation of a 0.25 µM 
solution of GCN4-bb with increasing concentrations of a double 
stranded oligonucleotide (AP1hs•AT) containing the composite 
consensus binding site (TCAT·AAATT) led to a notable and 
progressive increase in the fluorescence emission (lexc 329 nm). 
Curiously, the resulting titration curve exhibited an atypical shape, 
consisting on a spike in the emission intensity at low DNA/hybrid 
ratios, followed by a gradual increase as in a conventional saturation 
curve, at higher DNA concentrations (Figure 4, left). This type of 
multiphasic profile has been previously observed in reverse 
titrations for the interaction of cationic proteins with DNA, 15 and 
could be explained in terms of the competitive formation of multiple 
non-specific complexes with the DNA oligomers at low DNA/ligand 
ratios. Upon increasing the DNA concentration, the 1:1 binding 
mode becomes predominant, and the curve follows a more familiar 
titration profile, consistent with the results observed in the gel shift 
experiments (note that the EMSA experiments were performed as 
forward titrations: constant DNA concentration and addition of the 
peptide). 
 
Figure 4. Left: Fluorescence emission titration of a 0.25 µM solution of GCN4-bb with 
a dsDNA containing the target sequence (AP1hs•AT) in Tris-HCl buffer 20 mM pH 7.5, 
100 mM NaCl. Solid line represents a nonlinear fit to a mixed model considering a 1:1 
complex and competitive species resulting from non-specific binding; dashed line 
represents the best fit to a simple 1:1 binding mode, discarding points 2 to 9 in the 
titration. Right: Titration of a 0.5 µM solution of GAGA-bb with a DNA containing the 
composite recognition site (AT•GAG) in Tris-HCl buffer 20 mM pH 7.5, 100 mM 
NaCl. Solid line represents the nonlinear fit to a 1:1 binding mode for AT•GAG, and a 
mixed mode including competitive nonspecific binding for the GC-rich oligonucleotide. 
In contrast with the relatively complex binding profile displayed by 
the GCN4-bb hybrid, fluorescence titration of a 0.50 µM solution of 
the zinc-finger conjugate GAGA-bb with its target DNA 
(AT•GAG), containing the composite binding sequence 
(AATT·GAG), could be fitted to a simple 1:1 binding mode with an 
apparent KD of ≈12 nM, (Figure 2, right).16 Titration of this same 
hybrid with a G/C-rich double stranded DNA, resulted in a 
multiphasic profile with a very small increase in the emission 
intensity from the minor groove binder, in line with the expected 
low affinity for this oligonucleotide sequence. Control experiments 
with the bisbenzamidine 6, which also contains a charged side chain 
with two amine groups, are consistent with this analysis, 
demonstrating low affinity for G/C-rich oligonucleotides and high 
affinity binding for A/T-rich sites (see the supporting information). 
 
Taken together, these results demonstrate that 
bisbenzamidines are synthetically straightforward minor groove-
binding handles for the construction of functional conjugates with 
TF peptide fragments, which, by themselves, are not capable of 
binding to the DNA. In addition to the thermodynamic stabilization 
of otherwise unstable complexes, these anchors display marked 
fluorogenicity that allowed us to observe molecular associations that 
are not evident in regular gel shift studies.  
Conclusion 
In summary, we have demonstrated that conjugation of fragments of 
transcription factors to bisbenzamidines allows the selective DNA 
recognition of relatively long DNA sequences, containing composite 
sites of the original TF target sequence and A/T-rich sites targeted 
by the minor groove binder. Moreover, the fluorogenic nature of the 
minor groove binder allows to monitoring the DNA recognition 
process by fluorescence spectroscopy. Therefore, the combination of 
standard EMSA analysis and fluorescence titrations provides a more 
exact account of the processes taking place when these hybrids 
interact with the DNA. Given the ready accessibility of the minor 
groove binders, its optical sensing properties and the nanomolar 
affinities and selectivity exhibited by the conjugates, we expect a 
great future for this DNA binding strategy. 
Experimental Section 
General synthetic procedures: All reagents were from commercial sources: DMF and 
TFA were purchased from Scharlau, CH2Cl2 from Panreac, CH3CN from Merck. The 
rest of reagents were from Sigma-Aldrich. When indicated, reactions were monitored by 
analytical RP-HPLC with an Agilent 1100 series LC/MS with an Eclipse XDBC18 (4.6 
× 150 mm, 5 µm) analytical column. Standard conditions for analytical RP-HPLC 
consisted on an isocratic regime during the first 5 min, followed by a linear gradient 
from 5% to 75% of solvent B for 30 min at a flow rate of 1 mL/min (A: water with 
0.1% TFA, B: CH3CN with 0.1% TFA). Compounds were detected by UV absorption. 
Amidine derivatives 2, 3 and 5 were purified on a Büchi Sepacore preparative system 
consisting on a pump manager C-615 with two pump modules C-605 for binary solvent 
gradients, a fraction collector C-660, and UV Photometer C-635. Purification was made 
using reverse phase linear gradients of MeOH/H2O 0.1% TFA in 30 min with a flow 
rate of 30 mL/min, using a pre-packed preparative cartridge (150 × 40 mm) with reverse 
phase RP18 silica gel (Büchi order #54863). The fractions containing the products were 
freeze-dried, and their identity confirmed by ESI-MS and NMR. Compounds were 
isolated as TFA salts. The peptide conjugates GCN4-pr, GCN4-bb and GAGA-bb 
were purified by analytical RP-HPLC, using an Eclipse XDBC8 (4.6 × 150 mm, 5 µm) 
analytical column, following standard HPLC purification conditions. The sequences of 
the peptides are: Asp226 to Gln248 of GCN4: DPAALKRANTEAARRSRAE245KLQ; 
Ser28 to Phe58 of GAGA: SQSEQPATCPICYAVIK44QSRNLRRHLELRHF. 
N-(3-{[(tert-butoxy)carbonyl](5-oxopentyl)amino}propyl)carbamate 4-[2-({5-[(3-
aminopropyl)amino]pentyl}amino)-3-(4-carbamimidoylphenoxy)propoxy] benzene 
carboximidamide (3). The amine 29b (90 mg, 0.13 mmol), and tert-butyl (3-((tert-




















































dissolved in MeOH (1.25 mL) in a round bottom flask. NaBH3CN (8 mg, 0.12 mmol) 
was added over the solution, and the mixture was stirred for 5 h at rt. The solvent was 
removed under reduced pressure, and the residue was purified by preparative reverse-
phase chromatography. The fractions containing the desired product were collected, 
concentrated and freeze-dried to obtain the desired conjugate. The isolated Boc-
protected compound was dissolved in CH2Cl2 (1 mL) and cooled to 0 ºC. TFA (1 mL) 
was added dropwise, and the resulting solution was stirred at 0 ºC for 1h, and at rt for 
other 2 h. The solvent was removed under reduced pressure, and the residual TFA was 
removed by co-distillation with CH2Cl2. The freeze-dried white powder was identified 
as the desired product (3) (65.0 mg, 0.08 mmol, 65% overall yield for the two-step 
process). 1H NMR (400 MHz, DMSO-d6 δ): 1.38 (m, 2H), 1.62 (m, 2H), 1.71 (m, 2H), 
1.91 (m, 2H), 2.88 (m, 4H), 2.99 (m, 2H), 3.16 (m, 2H), 4.08 (m, 1H), 4.54 (d, J = 4.5 
Hz, 4H), 7.21 (d, J = 8.9 Hz, 4H), 7.87 (d, J = 8.8 Hz, 4H), 8.03 (s, 2H, NH), 8.89 (s, 
1H, NH), 9.23 (s, 4H), 9.34 (s, 4H), 9.53 (s, 1H, NH). 13C NMR (400 MHz, DMSO-d6 
δ): 23.5 (CH2), 24.2 (CH2), 25.4 (CH2), 25.6 (CH2), 36.6 (CH2), 44.3 (CH2), 46.2 (CH2), 
47.0 (CH2), 55.7 (CH), 65.3 (CH2), 115.4 (CH), 121.0 (C), 139.6 (CH), 159.2 (q, C 
TFA), 162.2 (C), 165.2 (C). ESI+-MS: [M+H] calcd. for C25H40N7O2 = 470.3238 found 
470.3236.). 
Synthesis of 4-({[3-({5-[(3-aminopropyl)amino]pentyl}oxy)-5-{[(4-carbamimidoyl 
phenyl)amino]methyl}phenyl]methyl}amino)benzene-1-carboximidamide (6). 
Potassium tert-butoxide (36.4 mg, 0.324 mmol, 4 equiv) was added to a solution of the 
bis-amino benzamidine 58a (50 mg, 0.081 mmol) in dry DMSO (1.62 mL). After 30 min, 
tert-butyl-[3-[(tert-butoxycarbonyl)amino]propyl](5-iodopentyl)carbamate (46.3 mg, 
0.097 mol, 1.2 equiv) was added in portions. The reaction mixture was stirred under Ar 
at rt for 2 h. The crude reaction was directly purified by preparative reverse-phase 
chromatography (Büchi Sepacore) (gradient: 15% B, 5 min; 15% → 95 % B, 30 min.). 
The combined fractions were concentrated and freeze-dried. 
The isolated Boc-protected amine was dissolved in CH2Cl2 (2 mL) and cooled to 0 ºC. 
TFA (2 mL) was added dropwise and the resulting solution was stirred at 0 ºC for 1h 
and at room temperature for other 2 h. The solvent was removed under reduced pressure, 
and the residual TFA was removed by co-distillation with CH2Cl2. The residue was 
purified by preparative reverse-phase chromatography (Büchi Sepacore) (gradient: 0% 
B, 5 min; 0% → 50 % B, 30 min.). The freeze-dried solid was identified as the desired 
product (6) as a white powder (56.8 mg, 0.072 mmol, 89% overall yield for the two-step 
process). 1H NMR (400 MHz, MeOD-d4 δ): 1.32 (m, 2H), 1.55 (m, 2H), 1.77 (m, 2H), 
2.07 (m, 2H), 3.05 (m, 2H), 3.11 (m, 2H), 3.94 (t, J = 6.1 Hz, 2H), 4.36 (s, 4H), 6.68 (d, 
J = 8.9 Hz, 4H), 6.79 (s, 2H), 6.94 (s, 1H), 7.57 (d, J = 8.9 Hz, 4H). 13C NMR (400 
MHz, MeOD-d4 δ): 24.2 (CH2), 25.3 (CH2), 27.0 (CH2), 29.9 (CH2), 37.8 (CH2), 45.8 
(CH2), 47.5 (CH2), 49.0 (CH2), 68.5 (CH2), 112.8 (CH), 113.1 (CH), 114.3 (C), 118.9 
(CH), 130.6 (CH), 142.3 (C), 155.4 (C), 161.2 (C), 167.1 (C). ESI+-MS: [M+H] calc. 
for C30H43N8O = 531.3554 found 531.3559). 
Peptide synthesis. All peptide synthesis reagents and amino acid derivatives were from 
GL Biochem (Shanghai) and Novabiochem; amino acids were used as protected Fmoc 
amino acids with the standard side chain protecting scheme, except for the orthogonally 
protected Fmoc-Lys(alloc)-OH and Fmoc-Glu(alloc)-OH, which were purchased from 
Bachem. C-terminal amide peptides were synthesized on a 0.1 mmol scale using a 
Fmoc-PAL-PEG-PS resin from Applied Biosystems. All solvents were dry and synthesis 
grade. Peptides were synthesized using an automatic PS3 peptide synthesizer from 
Protein Tecnologies. Amino acids were coupled in 4-fold excess using HBTU/HOBt as 
activating agent. Each amino acid was incubated with the HBTU/HOBt mixture for 30 
seconds in DMF before being added onto the resin. Peptide bond-forming couplings 
were conducted for 30 min to 45 min.  
Deprotection of the temporal Fmoc protecting group. Deprotection of the temporal 
Fmoc was performed by treating the resin with 20% piperidine in DMF solution for 10 
min. N-terminal acetylation. The N-acetylation coupling was performed immediately 
after Fmoc deprotection by treating the resin with Ac2O/(DIEA/DMF 0.195 M) 2:1. 
Allyl and Alloc removal. The selective deprotection of the glutamic acid residues was 
carried out as following: approx. 3.5 µmol (25 mg of resin) of the peptide attached to 
the solid support were treated with PPh3 (1.5 equiv), N-methyl morpholine (10 equiv) 
and phenylsilane (10 equiv) in CH2Cl2 (400 µL) at rt for 15 min. Subsequently 
Pd(OAc)2 (0.3 equiv) was added and the resulting mixture was stirred overnight. The 
selective deprotection of the lysine was carried out treating the peptide attached to the 
resin with Pd(PPh3)4 (1 eq), morpholine (190 eq) in H2O/CH2Cl2 2% (400 µL) . The 
resin was filtered and washed with DMF (2 × 1.5 mL × 2 min), diethyl dithiocarbamate 
(DEDTC, 25 mg in 5 mL of DMF, 2 × 1.5 mL × 5 min), DMF (2 × 1.5 mL × 2 min) and 
CH2Cl2 (2 × 5 mL × 2 min). Cleavage/deprotection step. The resin containing the 
desired peptide is washed with CH2Cl2 (2 × 1.5 mL × 2 min) and filtered; A mixture of 
50 µL of CH2Cl2, 25 µL of H2O, 25 µL of triisopropylsilane (TIS), and 900 TFA µL for 
every 40 mg of resin is added onto the resin, and the mixture is shaken for 2.5 h. The 
resin is filtered and the liquid is added over 10 volumes of cold Et2O. After 5 min the 
suspension is centrifuged and the resulting white residue is washed twice with Et2O and 
dried under an Ar current. 
Synthesis of GCN4-pr. The resin-bound selectively deprotected GCN4 peptide (25 mg, 
aprox, 3.5 µmol) was shaken for 1 h in DMF and then filtered. A mixture of HATU (3 
mg, 7.90 × 10–3 µmol) in DMF (170 µL), and DIEA (28 µL, of a 0.5 M solution in 
DMF) was added to the resin, shaken for 5 min and the resin washed with DMF (2 × 1.5 
mL × 2 min). Finally, a mixture of functionalized propamidine 3 (≈ 5 mg, ≈ 7 µmol) in 
DIEA (56 µL, of a 0.5 M solution in DMF) was added to the resin and shaken for 2 h. 
The resin was washed with DMF (2 × 1.5 mL × 2 min) and filtered. The peptide 
deprotection and resin cleavage step was carried out following standard conditions, and 
the resulting crude mixture was purified by RP-HPLC obtaining the desired hybrid (3.0 
mg, 1.74 µmol, overall yield considering the peptide synthesis ≈ 25%). Analytical Data 
of the purified products: MS: MALDI-TOF (M+H+): calcd. for C134H229N49O36 = 3100.7, 
found 3101.2. Retention time = 22.0 min. Peptide GCN4-bb was synthesized following 
the same procedure but using the amine 6 for the coupling reaction (see the supporting 
information for experimental details). 
Synthesis of GAGA-bb. The resin-bound GAGA peptide (28 mg, aprox. 2.3 × µmol) 
was suspended in DMF (1 mL), shaken for 1 h and then filtered. A mixture of succinic 
anhydride (127 µL, 0.1 M in DMF, 18 µmol, 8 equiv), DIEA (36 µL, 0.5 M in DMF, 18  
µmol, 8 equiv) and DMAP (28 µL, 0.2 M in DMF, 5.6 µmol, 2 equiv) was added, and 
the resulting resin suspension was shaken for 1 h at rt. The resin was then filtered and 
washed with DMF (3 × 0.6 mL). A mixture of HATU (172 µL, 52 mM in DMF, 9.1 
µmol, 4 equiv) and DIEA (36 µL, 0.5 M in DMF, 18 µmol, 8 equiv) was added. The 
resulting mixture was shaken for 5 min and filtered. A solution of the bis-benzamidene 
6 (9.1 mg in 200 µL of DMF, 4 equiv.) and DIEA (36 µL, 0.5 M in DMF, 18 µmol, 8 
equiv) was added. The mixture was shaken for 2.5 h after which the resin was filtered 
and washed with DMF (3 × 0.6 mL, 5 min) and Et2O (2 × 0.5 mL, 5 min). The cleavage 
step was performed following standard conditions, and the desired peptide conjugate 
purified by RP-HPLC. Analytical Data of the purified products: MS: MALDI-TOF 
(M+H+): calcd. for C195H304N60O49S2 = 4337.0, found 4337.2. Retention time = 21.4 min. 
Fluorescence Spectroscopy. Measurements were made with a Jobin-Yvon Fluoromax-
3, (DataMax 2.20) coupled to a Wavelength Electronics LFI−3751 temperature 
controller, using the following settings: increment: 1.0 nm; integration time: 0.2 s; 
excitation slit width: 3.0 nm; emission slit width: 6.0 nm; excitation wavelength 329 nm. 
The emission spectra were acquired from 345 to 500 nm at 20 ºC. All titrations were 
made following the same procedure: to 1 mL of either compound (50 nM in the case of 
6, 250 nM in the case of GCN4-bb or 500 nM  for GAGA-bb) in Tris-HCl buffer 20 
mM pH 7.5, 100 mM NaCl, aliquots of ≈ 200 µM stock solutions of the respective 
dsDNAs were successively added, and the fluorescence spectrum was recorded after 
each addition.  In the case of the titration of GAGA-bb before adding the first aliquot of 
dsDNA, 5 equiv of ZnCl2 were added to make the complex. 
Electrophoretic mobility shift assays (EMSA) were performed with a BIO-RAS Mini 
Protean gel system, powered by an electrophoresis power supplies PowerPac Basic 
model, maximum power 150 V, frequency 50.60 Hz at 140 V (constant V).  
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 Conjugation of fragments of bZIP and zinc finger transcription factors to 
bisbenzamidines allows the selective DNA recognition of composite DNA 
sequences containing the original target sequence of the peptide fragment in 
tandem with A/T-rich sequences targeted by the minor groove binder unit. 
The fluorogenic aza-bisbenzamidine is exploited for the spectroscopic 
characterization of the DNA recognition process. 
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